We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Show more
Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.26 | -3.94537177542 | 6.59 | 7.41 | 6.02 | 1039145 | 6.62156622 | CS |
4 | -6.91 | -52.1903323263 | 13.24 | 13.24 | 6.02 | 1693603 | 7.99983058 | CS |
12 | -4.56 | -41.8732782369 | 10.89 | 19.34 | 6.02 | 1327503 | 11.52423879 | CS |
26 | -3.08 | -32.7311370882 | 9.41 | 20.12 | 6.02 | 1511131 | 12.03075007 | CS |
52 | -9.39 | -59.7328244275 | 15.72 | 21.4199 | 6.02 | 1088670 | 13.09609304 | CS |
156 | -23.67 | -78.9 | 30 | 78 | 6.02 | 865162 | 21.89453519 | CS |
260 | -23.67 | -78.9 | 30 | 78 | 6.02 | 865162 | 21.89453519 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions